Research and Markets: Ocrelizumab (Multiple Sclerosis) – Forecast and Market Analysis to 2022

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/p32xmw/ocrelizumab) has announced the addition of the "Ocrelizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022" report to their offering.

Ocrelizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFN) agents: Bayer's Betaseron/Betaferon (IFN-1b), Biogen's Avonex (IFN-1a) and Merck's Rebif (IFN-1a), and Teva's Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.

Roche's/Genentech's and Biogen Idec's ocrelizumab (RG1594) is a recombinant humanized CD20 mAb that is currently being investigated in Phase III trials for the treatment of RRMS and PPMS. The drug is a more humanized version of chimeric Rituxan (rituximab), which previously demonstrated notable clinical benefits and is commonly prescribed off-label for MS. However, a Phase III trial evaluating Rituxan in MS was not initiated due largely to Rituxan's 2015 US patent expiry date (2014 in the EU) (GlobalData, 2012).

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

Read the rest here:
Research and Markets: Ocrelizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022